This study evaluated the clinical efficacy and safety of bromfenac 0.09%, sodium hyaluronate 0.4% (SH) combination therapy, versus placebo and SH in a clinical model of pterygium I-III. A total of 166 eyes (99 patients) with pterygium grade I-III were randomized to bromfenac 0.09% ophthalmic solution+SH 0.4% or placebo+SH 0.4%. This was a Phase IV, prospective, parallel, double-masked, multicenter clinical trial. One drop of bromfenac or placebo was instilled two times a day (BID) for 20 days, both groups accompanied treatments with one drop of SH three times a day (TID). The primary efficacy endpoints were the conjunctival hyperemia and the Ocular Surface Disease Index (OSDI) score. Other results measured included burning, foreign body sensation, and photophobia. The safety was assessed by the tear break-up time (TBUT), visual acuity (VA), IOP, lissamine green, fluorescein stains, and the incidence of adverse events (AEs). Compared with baseline, there was a significant reduction in the conjunctival hyperemia (=0.0001) and OSDI score in both groups (=0.0001). There was a significant improvement in ocular symptomatology for both, placebo/SH and bromfenac/SH groups (=0.0001), the decrement in the ocular burning was 41.1% vs 24.6%, the foreign body sensation was 31.5% vs 36.2% and, for photophobia was 23.3% vs 30.5%, respectively. A statistically significant difference was observed in TBUT for bromfenac/SH (=0.045), at day 20. There were no significant alterations in IOP (=0.068) or VA (=0.632). Similar improvements were observed in the fluorescein and green lissamine staining. Finally, the incidence of AE was similar between groups. The treatment with bromfenac 0.09% ophthalmic solution and SH 0.4% combination therapy for 3 weeks reduced clinical signs, in patients with pterygium I-III. The results suggest that bromfenac 0.09% can improve the symptomatology, reduce the presentation of clinical signs associated with superficial ocular inflammation.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6507105 | PMC |
http://dx.doi.org/10.2147/OPTH.S203648 | DOI Listing |
J Cataract Refract Surg
April 2019
Wake Forest Baptist Eye Center, Winston-Salem, North Carolina, USA.
Purpose: To determine whether the addition of phenylephrine 1.0%-ketorolac 0.3% (Omidria) to the irrigation solution during femtosecond laser-assisted cataract surgery (FLACS) reduces surgical time and the need for pupil expansion devices compared with the irrigation solution containing epinephrine.
View Article and Find Full Text PDFNippon Ganka Gakkai Zasshi
April 1995
New Drug Research Laboratories, Senju Pharmaceutical Co., Ltd, Hyogo-ken, Japan.
We studied the effects of bromfenac sodium (BF) on several types of acute ocular inflammation. BF inhibited the production of prostaglandins from rabbit iris-ciliary body by 50% at a concentration of 1.1 microM and was 3.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!